目的:观察卡培他滨(希罗达)联合健脾化痰方治疗老年肠癌根治术后患者的临床疗效。方法:将60例老年肠癌根治术后患者随机分为2组各30例,西医组给予卡培他滨(希罗达)化疗8个周期;中西医组在化疗的同时服用健脾化痰方治疗;观察2组一般指标、1、2、3、4年的无病生存率、临床症候疗效、药物毒性反应、KPS行为状态量表、生命质量(QOL)。结果:1、2、3、4年的无病生存率对照组分别为97.5%、89.2%、73.9%、59.2%;中西医组分别为100%、92.5%、84.3%、81.7%,中西医组的4年无病生存率明显高于对照组,2组比较,差异有显著性意义(P<0.05)。临床症候总改善率中西医组为83.3%,对照组为46.7%,中西医组优于对照组,差异有显著性意义(P<0.05)。白细胞减少对照组与中西医组发生率分别为63.3%和46.7%;恶心呕吐对照组与中西医组发生率分别为60.0%和43.3%;腹泻对照组与中西医组发生率分别为50.0%和30.0%。血液学毒性、胃肠道反应发生率中西医组均低于对照组,2组比较,差异均有显著性意义(P<0.05)。肝功能异常、手足综合征中西医组发生率也低于对照组,但2组比较,差异均无显著性意义(P>0.05)。中西医组患者治疗后KPS/QOL评分均有明显升高,与治疗前比较,差异均有显著性意义(P<0.05);2组KPS/QOL评分治疗后比较,差异均有显著性意义(P<0.05)。结论:与单纯化疗相比较,卡培他滨(希罗达)联合健脾化痰方治疗老年肠癌根治术后患者能提高患者无病生存率,改善临床症候,减轻化疗毒副反应,改善生活质量。 Objective: To observe the clinical efficacy of capecitabine (Xeloda) in combination with Jianpi Huatan Fang in the treatment of elderly patients with rectal cancer after radical operation. Methods: Sixty elderly patients with colorectal cancer after radical surgery were randomly divided into two groups of 30 patients. Western medicine group was given capecitabine (Xeloda) chemotherapy for eight cycles. The Chinese and Western medicine group took chemotherapy combined with spleen and phlegm Side treatment. The two groups of general indicators, no disease-free survival rate, clinical symptom response, drug toxicity response, KPS behavior status scale and quality of life (QOL) were observed after one, two, three and four years. Results: The rates of disease-free survival in 1, 2, 3 and 4 years were 97.5%, 89.2%, 73.9% and 59.2% respectively in the control group, 100%, 92.5%, 84.3% and 81.7% The 4-year disease-free survival rate was significantly higher in the control group than in the control group. There was significant difference between the two groups (P <0.05). The total clinical symptom improvement rate was 83.3% in the Western medicine group and 46.7% in the control group, which was better in the Western medicine group than in the control group (P <0.05). The incidence of leukopenia in control group and that of western medicine group were 63.3% and 46.7% respectively. The incidence rates of nausea and vomiting in control group and western medicine group were 60.0% and 43.3% respectively. The incidence rates of diarrhea control group and western medicine group were 50.0% 30.0%. Hematological toxicity and gastrointestinal reactions were lower in the Western and Chinese medicine groups than in the control group. There was significant difference between the two groups (P <0.05). Liver dysfunction, hand-foot syndrome in Western medicine group incidence is also lower than the control group, but the two groups, the difference was not significant (P> 0.05). The scores of KPS / QOL after treatment in both groups were significantly higher than those before treatment (P <0.05). There was significant difference between the two groups in KPS / QOL scores after treatment (P <0.05) P <0.05). Conclusions: Compared with chemotherapy alone, capecitabine (Xeloda) combined with Jianpi Huatan Fang can improve disease-free survival rate, improve clinical symptoms, relieve chemotherapy side effects and improve Quality of Life.